Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fedotozine SCHEMBL1649900 | 1.00 | OPRM1 (0.63) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Fedotozine SCHEMBL154629 | 1.00 | OPRM1 (0.63) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Fedotozine SCHEMBL11137933 | 0.91 | ALDH1A1 (0.71) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Fedotozine SCHEMBL11137984 | 0.91 | ALDH1A1 (0.71) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Fedotozine SCHEMBL9403100 | 0.90 | OPRM1 (0.61) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Fedotozine SCHEMBL9191830 | 0.90 | OPRM1 (0.61) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| SCHEMBL11389394 | 0.88 | OPRM1 (0.51) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| SCHEMBL9832151 | 0.84 | OPRM1 (0.46) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| SCHEMBL21286614 | 0.82 | OPRM1 (0.44) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| SCHEMBL11372319 | 0.82 | OPRM1 (0.45) | OPRM1OPRD1PDE4DNR1I2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5362756-A | Gastrointestinal disorders | JOUVEINAL S.A. (FR) | 1994-11-08 | — | — | US | claimed |
| US-5266599-A | Use of (+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine to increase gastric discharge in a subject | JOUVEINAL S.A. (FR) | 1993-11-30 | — | — | US | claimed |
| US-5245080-A | Gastrointentinal disorders | JOUVEINAL SA (FR) | 1993-09-14 | — | — | US | claimed |
| EP-0384088-B1 | (+)1-[(3,4,5-Trimethoxy)benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine, process for its preparation and its therapeutical use | JOUVEINAL S.A. (FR) | 1993-03-31 | — | — | EP | claimed |
| JP-2264749-A | — | — | None | — | — | JP | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | disclosed |
| US-20050136127-A1 | Trimebutine and/or fedotozine combined with laxatives, antidiarrheals, antibiotics, antiulceratives, gastric secretion inhibitors, peristalitc stimulants, serotonin (5HT3) receptor antagonists, serotonin (5HT4) receptor agonists and/or selective serotonin reuptake inhibitors | MCNEIL-PPC, INC | 2005-06-23 | — | — | US | disclosed |
| US-20040010034-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | disclosed |
| US-20040009234-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | disclosed |
| US-5245080-A | Gastrointentinal disorders | JOUVEINAL SA (FR) | 1993-09-14 | — | — | US | disclosed |
| EP-0384088-B1 | (+)1-[(3,4,5-Trimethoxy)benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine, process for its preparation and its therapeutical use | JOUVEINAL S.A. (FR) | 1993-03-31 | — | — | EP | disclosed |
| EP-0384088-B1 | (+)1-[(3,4,5-Trimethoxy)benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine, process for its preparation and its therapeutical use | JOUVEINAL S.A. (FR) | 1993-03-31 | — | — | EP | disclosed |
| JP-H02264749-A | (+)-1-((3,4,5-TRIMETHOXY)-BENZYLOXYMETHYL))-1-PHENYL-N,N-DIMETHYL-N-PROPYLAMINE | JOUVEINAL SA | 1990-10-29 | — | — | JP | disclosed |
| EP-0384088-A1 | (+)1-[(3,4,5-Trimethoxy)benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine, process for its preparation and its therapeutical use | JOUVEINAL S.A. (FR) | 1990-08-29 | — | — | EP | disclosed |
| EP-0384088-A1 | (+)1-[(3,4,5-Trimethoxy)benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine, process for its preparation and its therapeutical use | JOUVEINAL S.A. (FR) | 1990-08-29 | — | — | EP | disclosed |
| EP-0384088-A1 | (+)1-[(3,4,5-Trimethoxy)benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine, process for its preparation and its therapeutical use | JOUVEINAL S.A. (FR) | 1990-08-29 | — | — | EP | disclosed |
| US-4301163-A | ANTISPASMODIC AGENTS, ANESTHETIC, ANALGESICS | SOCIETE INDUSTRIELLE DE PRODUITS DE SYNTHESE (FR) | 1981-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRM1 814/4885OPRD1 1577/4885PDE4D 78/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRM1 814/4885OPRD1 1577/4885PDE4D 78/4885 |
| US-20040010034-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | OPRM1 3326/4885OPRD1 2321/4885PDE4D 885/4885 |
| US-20040009234-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | OPRM1 3326/4885OPRD1 2321/4885PDE4D 885/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | OPRM1 814/4885OPRD1 1577/4885PDE4D 78/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRM1 814/4885OPRD1 1577/4885PDE4D 78/4885 |
| US-20050136127-A1 | Trimebutine and/or fedotozine combined with laxatives, antidiarrheals, antibiotics, antiulceratives, gastric secretion inhibitors, peristalitc stimulants, serotonin (5HT3) receptor antagonists, serotonin (5HT4) receptor agonists and/or selective serotonin reuptake inhibitors | HTR4, HTR6, SLC6A4 | OPRM1 115/4885OPRD1 188/4885PDE4D 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.